OR-FLIR-SYSTEMS-INC
22.1.2019 17:01:13 CET | Business Wire | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) today announced the Raymarine DockSense™ assisted docking system, the marine industry’s first intelligent object recognition and motion sensing assisted docking solution for recreational boating. DockSense system uses FLIR machine vision camera technology and video analytics to integrate intelligence gathered from surrounding imagery with the vessel’s propulsion and steering system to assist boat owners in tight quarter docking maneuvering. Additionally, FLIR announced that Prestige Yachts, a Groupe Beneteau brand, will become the first to demonstrate the technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190122005313/en/
Docking a boat can be a stressful experience, even for the most experienced captains. Often wind and tides make the task more difficult, and docking mishaps can become expensive repairs and safety hazards. The DockSense system is designed to augment a captain's boat handling skills using the system’s Virtual Bumper™ zone technology around the vessel. Should an object like a piling or another vessel encounter the Virtual Bumper, DockSense automatically introduces corrective steering and throttle commands to avoid the object and assist the captain in guiding the vessel to the dock.
DockSense uses global positioning system (GPS) and attitude heading reference system (AHRS) position sensing technology to compensate for the effects of wind and currents, ensuring the vessel enters the dock without drama or costly collisions. The Raymarine DockSense system includes multiple FLIR machine vision cameras, a central processing module, and the DockSense App running on Raymarine’s Axiom navigation display. The system integrates with modern joystick propulsion systems, providing assisted steering and throttle commands to help captains make a smooth arrival.
“Raymarine DockSense assisted docking system embodies our focus on solutions by combining FLIR navigation, machine learning, and sensing technologies,” said Jim Cannon, President, and CEO of FLIR. “Most importantly, we bring these innovations together into a simple solution that addresses a key customer challenge by taking the stress out of docking a boat and makes the boating experience safer and more enjoyable for everyone onboard.”
“Our goal is to be the global benchmark for all boating experiences,” said Hervé Gastinel, CEO of Groupe Beneteau. “The Raymarine DockSense solution will give future Prestige owners the confidence to dock safely and aligns with our vision to simplify the boating experience and make boating accessible to a much larger audience”, confirms Erik Stromberg, Prestige product marketing director.
FLIR will preview Raymarine DockSense technology at the Dusseldorf Boat Show in, Germany from January 19 – 27 at the Raymarine stand (Hall 11, Stand A42 ) and the Prestige stand (Hall 6, Stand D57). DockSense will also be demonstrated on a Prestige 460 motor yacht during the Miami Boat Show in February 2019.
To learn more, visit http://www.raymarine.com/docksense .
About FLIR Systems
Founded in 1978 and headquartered in Wilsonville, Oregon, FLIR Systems is a world-leading maker of sensor systems that enhance perception and heighten awareness, helping to save lives, improve productivity, and protect the environment. Through its nearly 3,500 employees, FLIR's vision is to be "The World's Sixth Sense" by leveraging thermal imaging and adjacent technologies to provide innovative, intelligent solutions for security and surveillance, environmental and condition monitoring, outdoor recreation, machine vision, navigation, and advanced threat detection. For more information, please visit http://www.flir.com and follow @flir .
About Prestige
A major international brand, PRESTIGE has positioned itself in the highly exacting market of luxury motor yachts. Manufactured in Vendée – France and devised by yachtsmen for those who love the sea, PRESTIGE® yachts are the jewel of French marine engineering. With the Garroni Studio, PRESTIGE designs the most livable yachts from 40 to 75 feet. Both FLYBRIDGE and SPORT ranges offer contemporary, high-design and clever motor yachts. The brand relies on an ever-growing worldwide professional dealer network. For more information please visit http://www.prestige-yachts.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190122005313/en/
Contact:
FLIR Media Contact Tim McDowd 503-498-3146 tim.mcdowd@flir.com
FLIR Investor Relations Jay Gentzkow 503-498-3809 Jay.gentzkow@flir.com
Prestige Press contact Elise Vinet +33670643397 e.vinet@jeanneau.fr
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom